Journal of Diabetes & Metabolism

Diabetic Ketoacidosis among COVID-19 Patients Admitted to Suhar Hospital, Oman: Clinical Characteristics and Outcomes

Ali Al-Reesi^1* and Hamed Al-Reesi^{2 *}Correspondence: Ali Al-Reesi, Consultant Endocrinologist, Head of Internal Medicine Department, Suhar Hospital, Ministry of Health, Oman, Tel: 0096899344839, Email: ,

Author info »

Introduction

The noval COVID-19 has been recognized as one of severe and fatal causes for viral pneumonia in the city of Wuhan, China in December 2019 with highly infectivity among humans [1]. As an outbreak, COVID-19 began in china and then has spread to most countries around the world. The number of confirmed cases is increasing dramatically every day [2]. In Oman, the first case was detected on 24th February 2020 and then cases started to increase gradually.

Diabetes mellitus (DM), particularly prolonged uncontrolled, impairs immune system and makes patients at high risk for infection [3]. Previous research on the Middle East Respiratory Syndrome (MERS)-corona, Severe Acute Respiratory Syndrome (SARS) and Community Acquired Pneumonia showed that patients with known DM or newly diagnosed DM are associated with high mortality and morbidity and similarly for COVID-19 [4–7]. Recent studies revealed that hospitalized patients admitted with DM and COVID-19 have prolonged length of admission stay and associates with high mortality rate, especially among elderly compared to young patients [8,9]. In Oman, DM was found to be the most common co- morbidity among hospitalized COVID-19 patients, followed by hypertension, chronic kidney disease and ischemic heart disease [10].

Diabetic ketoacidosis (DKA) is one of acute complications among COVID-19 patients with DM [9]. There are some of poor prognostic indicators in patients who developed DKA during COVID-19 infections like poor blood sugar control, mechanical ventilations and severe metabolic acidosis [9]. DKA occurs mainly in type 1 DM (T1DM) patients due to autoimmune destruction of Beta cells in pancreas which are responsible for insulin secretion. DKA occurs as secondary of relative or absolute insulin deficiency, leading to increased glucose production via gluconeogenesis and glycogenolysis and absolute insulin deficiency stimulating lipolysis, resulting in ketone production [11]. DKA can be presented in COVID-19 among type 2 DM (T2DM) patients triggered by severe infections [12]. Hospitalized DM patients could be already well known to have T1DM, T2DM or undiscovered DM i.e. HbA1c is more than or equal 6.5% otherwise it is a result of stress illness [13].

As DM is a common co-morbidity among COVID-19 patients in Oman [10], there is a need to investigate its complications, especially DKA. Therefore, the aim of this study is to describethe prevalence, clinical characteristics and outcomes in patients with DKA and COVID-19 admitted to Suhar Hospital, Oman

Methods

A retrospective review of DKA patients admitted to Suhar Hospital, Oman, from March 2020 to August 2020 was used as a method for the study. DKA patients were classified as with or without laboratory-confirmed COVID-19. DKA was defined as pH<7.3 and/or bicarbonate<18 mmol/L, blood glucose>13.9 mmol/L (250 mg/dL) and high ketones in urine or blood, and increased anion gap metabolic acidosis>12 [14]. The American Diabetes Association classifies DKA by severity as mild, moderate, or severe depending on the degree of acidosis (along with decrease in bicarbonate) and altered sensorium [15]. Al-Shifa’a system was used to extract patients’ demographic, laboratory and clinical characteristics. SPSS, version 22, was used to describe numerical variables (median, interquartile range-IQR) and categorical variables (frequencies and percentages). Due to the small sample size, non- parametric tests were used to investigate the statistical differences and associations at 5% significance level. Chi-square test, Fisher’s exact test and likelihood ratios chi-square test were used to test differences between categorical variables and Mann- Whitney U test was used to investigate differences of categorical variables (with two groups) in term of numerical variables.

This research was approved by the Research and Ethical Review and Approval Committee in North Batinah Governorate (NBG-RERAC15- 2020). Permission from Suhar hospital was achieved to extract patients’ data, and thus no informed consent from patients was required.

Results

A total of 14895 laboratory-confirmed COVID-19 patients were registered in North Batinah Governorate till August, 2020. Of them, 907 patients were admitted to Sohar hospital accounting for 6.1%. A total of 27 patients were found to fulfill the diagnostic criteria for Diabetic Ketoacidosis (DKA) in Suhar hospital during the study period (March-August 2020). Of them, 48% (n=13) cases were reported to present with COVID-19 representing a prevalence of 1.4% of COVID-19 admitted patients (13/907). The majority of DKA patients were females(52%), known diabetic (67%), with T1DM (67%), managed with insulin (74%), without ICU admission (74%) and discharged (85%). DKA patients had a median age of 33 years (IQR=21.0) and admitted for a median of 3 days (IQR=3.0).

Presence of COVID-19

Table 1 shows the characteristics of DKA patients by the presence of COVID-19. The majority of COVID DKA were males (54%), while most non- COVID DKA were females (57%). COVID DKA patients were older compared to non-COVID DKA patients (Median=36 years vs. 22 years) and significantly (p<0.05) had a longer length of stay (Median=5 days vs. 2 days). The majority of DKA patients presented with COVID-19 had pre-existing DM (67%), and the remaining 23% were newly diagnosed during admission. In comparison, 43% of DKA patients without COVID-19 were new DM cases. DKA patients with COVID mainly had T2DM (62%), whereas 93% of DKA patients without COVID had T1DM (Figure 1).

Table 1: Characteristics of DKA patients with or without infection with COVID-19.

Figure 1: COVID and non-COVID DKA patients by DM status.

All non-COVID patients had normal CXR, while 62% of COVID patients had bilateral radiological infiltrates (15 % with minimal and 46 % with extensive infiltrates). Six of DKA patients with COVID (46%) were admitted to the ICU compared to just one DKA patient without COVID (7%). Almost a third (31%) of DKA patients with COVID required mechanical ventilation (MV) compared to none of the DKA patients without COVID. Four DKA patients with COVID (33%) died compared to zero death among DKA patients without COVID. Both COVID and non-COVID patients had higher HbA1c (Median 10.3 vs. 12.8). Based on DKA criteria, COVID patients presented with lower pH (Median=7.0 vs. 7.2), lower bicarbonate (Median=6.2 vs. 11.1), and higher AG (Median=28.0 vs. 26.0). These indicated the severity of DKA among the COVID group. Furthermore, DKA patients with COVID presented significantly (p<0.05) with a higher values of serum Creatinine (Median=101.0 vs. 84.0) and CRP (Median=34.0 vs. 4.8) as well as a higher values of WBC (Median=11.8 vs. 8.9) and Neutrophils (Median=9.4 vs. 5.1) (Figure 2).

Figure 2: COVID and non-COVID DKA patients by clinical characteristics (median).

DKA Patients with COVID-19

The mortality proportion among DKA patients presented with COVID was 31% (n=4). Table 2 presents the investigation of characteristics that enhanced the occurrence of deaths among COVID DKA patients.Died DKA patients were slightly older than discharged patients (Median=37.5 vs. 36.0) with a higher length of stay (Median=5.5 vs. Mean=5.0). Deaths were equally distributed between males (50%) and females (50%).

Table 2: Characteristics of DKA patients with COVID-19 by outcome.

The outcome was associated with the severity of the COVID-19 conditions (p<0.05). All deceased patients presented with severe COVID pneumonia (100% vs. 11%), had extensive bilateral radiological infiltrates (100% vs. 22%), required ICU admissions (100% vs. 24%), and mechanical ventilations (100% vs. 0%). Compared to discharged patients, the majority of dead patients had pre-existing DM (75% vs. 78%), and the remaining (25% vs. 22%) were newly diagnosed during admission, as well as half of the dead patients had T1DM (50% vs. 33%) (Figure 3). In contrast to discharged COVID DKA patients, died patients significantly (p<0.05) presented withsevere DKA (Median PH=6.8 vs. 7.1 and Bicarbonate=4.4 vs. 8.8) as well as significantly (p<0.05) higher levels of inflammatory markers (Median WBC=19.5 vs.8.7 and Neutrophils=16.6 vs. 6.3) (Figure 4). Further exploration of the comorbidities among dead patients showed that none of them had been diagnosed with hypertension or ischemic heart disease. They developed complications such as ARDS, MV, RF and septic shock while only one of them developed MI.

Figure 3: DKA patients with COVID-19 by outcome, severity and diabetes status.

Figure 4: DKA patients with COVID-19 by clinical characteristics (median).

Discussion

In this retrospective observational study, we aimed to assess the clinical characteristics and outcomes of COVID-19 illness with diabetic ketoacidosis among hospitalized patients from March to August 2020. Few studies highlighted the presence of DKA among admitted COVID- 19 patients [12,16-19] and nationally, this is the first to our knowledge. Compared to previous studies, the current one provided analysis of 27 DKA cases of which 13 cases presented with confirmed COVID-19. This study estimated the prevalence of DKA among COVID-19 patients admitted to a secondary care hospital of 1.4%. This can be considered high prevalence concordant with a previous finding of 1.8% [18]. It is also high in terms of proportion (48%) out of total admitted DKA patients.

Compared to non-COVID DKA patients, most DKA patients with COVID-19 were males and older, and this result is similar to previous findings [18–20] and the prolonged length of hospital stay [16]. The findings showed that patients with confirmed COVID-19 had severe DKA compared to non-COVID patients as they presented with lower pH and bicarbonate and ahigher anion gap. This is explained by the unique pathophysiology of direct effects of SARS- CoV-2 on the pancreas via ACE2 receptors leading to damage of islets cells [21].

The association of COVID-19 with diabetes has been reported particularly among hospitalized patients [16,20], which is consistent with Oman [10]. This alarmed the need to investigate COVID-19 patients for DKA occurrence as a potential acute metabolic complication [22]. Previous COVID-19 studies revealed the impact of DM on the severity of COVID-19 as well as on the severity of COVID-19 illness, particularly among uncontrolled DM (either well known or newly discovered), consequently associating with the risk of severe acute complications like DKA and high mortality [4,8,9,12,23–25]. The clinical characteristics found in this study of high HbA1c values among DKA patients, either with (Median>10) or without (Median>12) COVID-19, indicated the alarming issue of uncontrolled DM, which increases the risk of DKA among admitted patients during pandemic era [26]. Recent literature found that patients who presented with severe COVID-19 disease are associated with high mortality [23,27], and this risk increased with the uncontrolled DM and DKA as both are associated with high mortality [23,24].

The current findings showed that, in comparison to discharged patients, all deceased DKA patients presented with COVID-19 had lower pH and bicarbonate while higher in AG and BS. This indicates the severity of DKA with both clinical and radiological severe COVID pneumonia. Besides, all deceased DKA patients required ICU admissions and mechanical ventilations. Therefore, these clinical features found among COVID DKA patients (high HbA1c, severe high anion metabolic acidosis, pH ≤ 6.9, ICU admissions and mechanical ventilations) indicated poor prognostic features. These findings are concordant with the recent literature that revealed the poor prognostic indicators (i.e. poor blood sugar control, mechanical ventilations and severe metabolic acidosis) in patients who developed DKA during COVID-19 infections [9,23,24].

This study had some noteworthy limitations. The study's sample size was small, which may limit the decision regarding the statistical significance versus the clinical effect. Small sample size brings limitations associated with the statistical analysis using non-parametric statistical tests instead of parametric tests [28,29]. This study involved only patients who got admitted to the hospital during the COVID-19 pandemic. The study does not represent stable patients inthe community. Therefore, results can only be generalized to hospitalized patients under similar settings. Also, COVID-19 affects several organs in the body, so some confounders may affect the association between DKA and COVID-19 and not considered in the study.

Conclusion

This study highlights the association between COVID-19 and DKA and its consequences of poor prognosis features and mortality rate of 31%. Admitted DKA patients with COVID-19 had prolonged length of hospital stay, occurred among T2DM, required ICU admissions and mechanical ventilation, and high mortality compared to non-COVID DKA patients. Low prognostic features among COVID-19 patients admitted with DKA include severe COVID pneumonia, severe metabolic acidosis, ICU admissions, mechanical ventilations, and high inflammatory markers. As uncontrolled DM puts patients at high risk for both DKA and severe COVID-19 disease, regular follow up is recommended at the primary care level for diabetic patients to keep their HBA1c less than 6.5-7% as advised by ADA, EASD and AACE. A large sample is required to further investigate and understand the association between DKA and COVID-19 in nature and incidence. This study also highlighted the need to update the guideline for the medical team to deal with DKA patients during the pandemic once admitted to the hospital.

Conflicts of Interest

The authors declared no conflict of interest.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors Contributions

Conception or design: A.K.S., H.K.Z.

Acquisition, analysis, or interpretation of data: A.K.S., H.K.Z. Drafting the work or revising: A.K.S., H.K.Z.

Final approval of the manuscript: A.K.S., H.K.Z.

Acknowledgement

This research was approved by the Research and Ethical Review and Approval Committee in North Batinah Governorate (NBGRERAC15- 2020).

References

1. Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy HA. Insights into the recent 2019 novel coronavirus (Sars-coV-2) in light of past human coronavirus outbreaks. Pathogens. 2020 4;9:186.
2. Habibzadeh P, Stoneman EK. The novel coronavirus: A bird’s eye view. Int J Occup Environ Med. 2020;11:65-71.
3. Iacobellis G. COVID-19 and diabetes: Can DPP4 inhibition play a role? Diabetes Res Clin Pract. 2020;162:1-2.
4. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr Clin Res Rev. 2020;14:303-310.
5. Jensen AV, Faurholt-Jepsen D, Egelund GB, Andersen SB, Petersen PT, Benfield T, et al. Undiagnosed Diabetes Mellitus in Community-Acquired Pneumonia: A Prospective Cohort Study. Clin Infect Dis. 2017;65:2091-2098.
6. Koskela HO, Salonen PH, Romppanen J, Niskanen L. Long-term mortality after community-acquired pneumonia - Impacts of diabetes and newly discovered hyperglycaemia: A prospective, observational cohort study. BMJ Open. 2014;4:e005715.
7. Lepper PM, Ott S, Nüesch E, Von Eynatten M, Schumann C, Pletz MW, et al. Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: Prospective cohort study. BMJ. 2012;344:e3397.
8. Alkundi A, Mahmoud I, Musa A, Naveed S, Alshawwaf M. Clinical characteristics and outcomes of COVID-19 hospitalized patients with diabetes in the United Kingdom: A retrospective single centre study. Diabetes Res Clin Pract. 2020;165:108263.
9. Chan KH, Thimmareddygari D, Ramahi A, Atallah L, Baranetsky NG, Slim J. Clinical characteristics and outcome in patients with combined diabetic ketoacidosis and hyperosmolar hyperglycemic state associated with COVID-19: A retrospective, hospital-based observational case series. Diabetes Res Clin Pract. 2020;166:108279.
10. Khamis F, Al-Zakwani I, Al Naamani H, Al Lawati S, Pandak N, Omar MB, et al. Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: An experience from Oman. J Infect Public Health. 2020;13:906-913.
11. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004;53:2079-2086.
12. Chee YJ, Ng SJH, Yeoh E. Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract. 2020;164:108166.
13. Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012 Jan;97(1):16-38.
14. Fayfman M, Pasquel FJ, Umpierrez GE. Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Med Clin North Am. 2017;101:587-606.
15. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32:1335-43.
16. Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab. 2020;22:1935-41.
17. Kim NY, Ha E, Moon JS, Lee YH, Choi EY. Acute hyperglycemic crises with coronavirus disease-19: Case reports. Diabetes Metab J. 2020;44:349-353.
18. Goldman N, Fink D, Cai J, Lee YN, Davies Z. High prevalence of COVID-19- associated diabetic ketoacidosis in UK secondary care. Diabetes Res Clin Pract. 2020;166:108291.
19. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020;31:1068-1077.
20. Reddy PK, Kuchay MS, Mehta Y, Mishra SK. Diabetic ketoacidosis precipitated byCOVID-19: A report of two cases and review of literature. Diabetes Metab Syndr. 2020;14:1459-1462.
21. Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24:422.
22. Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. Metabolism. 2016;65:507-21.
23. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.
24. Ahuja W, Kumar N, Kumar S, Rizwan A. Precipitating Risk Factors, Clinical Presentation, and Outcome of Diabetic Ketoacidosis in Patients with Type 1 Diabetes. Cureus. 2019;11:e4789.
25. Palermo NE, Sadhu AR, McDonnell ME. Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations. J Clin Endocrinol Metab. 2020;105:2819-2829.
26. Yan JH, Yang DZ, Deng HR, Li J, Weng JP. Incidence and related risk factors of diabetic ketoacidosis in Guangdong type 1 diabetics. Natl Med J China. 2013;93:897-901.
27. Henry BM, De Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chem Lab Med. 2020;58:1021-1028.
28. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487-493.
29. Cornell S. Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE. J Am Pharm Assoc. 2017;57:261-265.